| Title |
Author |
Type |
Date |
Words |
| BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration. |
|
|
Oct 18, 2017 |
1268 |
| Sutro Marks Two Drug Development Milestones. |
|
|
Oct 11, 2017 |
686 |
| Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer. |
|
|
Oct 10, 2017 |
1310 |
| Japan : Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. |
|
|
Oct 4, 2017 |
633 |
| United States : Gilead Presents Results From Phase 3 Study Evaluating Patients Who Switched to Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide From Boosted Protease Inhibitor-Based Regimens. |
|
Clinical report |
Oct 4, 2017 |
326 |
| Pharming Group share data from phase II clinical data for RUCONEST. |
|
|
Oct 2, 2017 |
217 |
| Pharming Announces Positive Data From Paediatric Clinical Trial With RUCONEST. |
|
|
Oct 2, 2017 |
1782 |
| Pharming reports safe data from RUCONEST clinical trial in children with hereditary angioedema. |
|
|
Oct 2, 2017 |
282 |
| Pharming reports safe data from RUCONEST clinical trial in children with hereditary angioedema. |
|
|
Oct 2, 2017 |
278 |
| Pharming Announces Positive Data from Paediatric Clinical Trial with RUCONEST. |
|
|
Sep 29, 2017 |
1758 |
| Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for Varicella Vaccine Candidate Against Chickenpox. |
|
|
Sep 25, 2017 |
934 |
| Enteris BioPharma doses first woman under Phase 2a clinical trial of Ovarest for treating endometriosis. |
|
|
Aug 25, 2017 |
268 |
| Enteris BioPharma doses first woman under Phase 2a clinical trial of Ovarest for treating endometriosis. |
|
|
Aug 25, 2017 |
264 |
| Enteris BioPharma Initiates Phase 2a Clinical Trial of Ovarest (oral leuprolide tablet) for Endometriosis. |
|
|
Aug 25, 2017 |
261 |
| Enteris BioPharma Doses First Woman in Phase 2a Clinical Trial of Ovarest(TM) (oral leuprolide tablet) for Endometriosis. |
|
|
Aug 24, 2017 |
729 |
| CEL-SCI Receives Permission from FDA to Resume Phase 3 Head and Neck Cancer Trial. |
|
|
Aug 15, 2017 |
263 |
| Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis. |
|
|
Aug 8, 2017 |
2169 |
| CTI BioPharma Announces Completion of Enrollment in the Phase 3 PIX306 Trial of PIXUVRI for Aggressive B-cell non-Hodgkin lymphoma. |
|
|
Aug 2, 2017 |
1028 |
| Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis. |
|
Clinical report |
Aug 2, 2017 |
2482 |
| CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib. |
|
|
Aug 1, 2017 |
714 |
| CTI BioPharma Corp enrols first patient in Phase two clinical trial of pacritinib. |
|
|
Aug 1, 2017 |
137 |
| RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial. |
|
|
Jul 27, 2017 |
853 |
| Bio Products Laboratory Presents New Phase 3 Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents or Reduces Bleeding Episodes in Children with Moderate to Severe Hereditary Factor X Deficiency. |
|
Clinical report |
Jul 12, 2017 |
1489 |
| ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement. |
|
|
Jul 10, 2017 |
995 |
| ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement. |
|
|
Jul 10, 2017 |
999 |
| BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration. |
|
|
Jul 10, 2017 |
1291 |
| Galapagos NV announces new Phase 2 study for filgotinib. |
|
Clinical report |
Jul 5, 2017 |
198 |
| Galapagos NV announces new Phase 2 study for filgotinib. |
|
Clinical report |
Jul 5, 2017 |
194 |
| GSK meets primary objective in phase three revaccination trial of Shingrix. |
|
|
Jun 23, 2017 |
205 |
| RedHill Biopharma announces positive top-line results from Phase III GUARD study with BEKINDA. |
|
Clinical report |
Jun 14, 2017 |
258 |
| RedHill Biopharma announces positive top-line results from Phase III GUARD study with BEKINDA. |
|
Clinical report |
Jun 14, 2017 |
254 |
| Japan : Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma. |
|
|
Jun 10, 2017 |
420 |
| Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting. |
|
|
Jun 5, 2017 |
1720 |
| BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors. |
|
|
Jun 1, 2017 |
1187 |
| Gilead Touts Positive Phase 3 Data on Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV-1. |
|
|
May 31, 2017 |
213 |
| Ireland,United Kingdom : Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS. |
|
|
May 24, 2017 |
338 |
| Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS. |
|
Report |
May 23, 2017 |
3240 |
| Kemwell Biopharma supplies biologics drug substance to US customer for Phase 1 clinical trials. |
|
|
May 18, 2017 |
173 |
| Kemwell Biopharma supplies biologics drug substance to US customer for Phase 1 clinical trials. |
|
|
May 18, 2017 |
169 |
| Kemwell Biopharma Supplies Biologics Drug Substance for Phase 1 Clinical Trials for US IND Filing. |
|
|
May 17, 2017 |
392 |
| Array BioPharma signs clinical trial collaboration agreement with Merck. |
|
|
May 11, 2017 |
211 |
| Array BioPharma signs clinical trial collaboration agreement with Merck. |
|
|
May 11, 2017 |
207 |
| RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017. |
|
|
May 9, 2017 |
1220 |
| PaxVax Initiates Clinical Trials of a Modernized Adenovirus Vaccine in Collaboration with the U.S. Army Medical Materiel Development Activity and the Walter Reed Army Institute of Research to Protect U.S. Military Personnel. |
|
|
May 8, 2017 |
1002 |
| Yisheng Biopharma Starts Enrollment in Phase 1 Immuno-Oncology Clinical Trial of YS-ON-001 in Patients with Advanced Solid Tumors. |
|
|
May 1, 2017 |
570 |
| Biotime forms subsidiary to develop programs focused on aging. |
|
|
Apr 17, 2017 |
238 |
| Biotime forms subsidiary to develop programs focused on aging. |
|
|
Apr 17, 2017 |
237 |
| Galapagos to complete three new Phase 2 proof-of-concept studies with filgotinib. |
|
|
Apr 4, 2017 |
212 |
| Galapagos to complete three new Phase 2 proof-of-concept studies with filgotinib. |
|
|
Apr 4, 2017 |
208 |
| Genentech to begin second Phase 3 trial for Alzheimer's therapy. |
|
|
Apr 1, 2017 |
111 |
| Paradigm Biopharmaceuticals sees success in hay fever clinical trials. |
|
|
Mar 23, 2017 |
237 |
| Paradigm Biopharmaceuticals sees success in hay fever clinical trials. |
|
|
Mar 23, 2017 |
233 |
| Roche's Genentech to begin new Phase III trial of Alzheimer's drug. |
|
|
Mar 1, 2017 |
271 |
| Roche's Genentech to begin new Phase III trial of Alzheimer's drug. |
|
|
Mar 1, 2017 |
267 |
| Bird flu vaccines poised to start clinical trials in China. |
|
|
Feb 20, 2017 |
295 |
| Bird flu vaccines poised to start clinical trials in China. |
|
|
Feb 20, 2017 |
291 |
| US FDA grants Qualified Infectious Disease Product fast-track designation to RedHill Biopharma's RHB-104. |
|
|
Jan 16, 2017 |
170 |
| US FDA grants Qualified Infectious Disease Product fast-track designation to RedHill Biopharma's RHB-104. |
|
|
Jan 16, 2017 |
174 |
| MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. |
|
|
Jan 12, 2017 |
176 |
| MorphoSys' partner Novartis to start Phase 2 trial with Bimagrumab in obese type 2 diabetes patients. |
|
|
Jan 12, 2017 |
172 |
| Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. |
|
|
Jan 9, 2017 |
174 |
| Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. |
|
|
Jan 9, 2017 |
170 |
| Galena Biopharma confirms the 505(b)(2) regulatory pathway for Phase 3 clinical trial design of GALE-401 for essential thrombocythemia. |
|
|
Dec 29, 2016 |
310 |
| Galena Biopharma confirms the 505(b)(2) regulatory pathway for Phase 3 clinical trial design of GALE-401 for essential thrombocythemia. |
|
|
Dec 29, 2016 |
306 |
| CTI BioPharma Announces Phase 3 Data from the PERSIST-2 Trial of Pacritinib to be Presented in Late-Breaking Session at ASH Annual Meeting. |
|
|
Nov 21, 2016 |
1755 |
| FDA Grants Fast Track Designation for Development of E2609, Eisai's BACE Inhibitor for Early Alzheimer's Disease. |
|
|
Nov 17, 2016 |
1039 |
| United States : Gilead announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis. |
|
Clinical report |
Nov 17, 2016 |
409 |
| United States : Catalent expert to present on clinical trial supply strategies for small and mid-size biopharma sponsors. |
|
|
Nov 14, 2016 |
307 |
| Pharming Announces the Presentation of the Results of the RUCONEST Phase II Study for Prophylaxis of Hereditary Angioedema Attacks. |
|
|
Nov 14, 2016 |
1463 |
| RegeneRx Biopharmaceuticals enrols first patients in ARISE-2 trial of RGN-259. |
|
|
Nov 11, 2016 |
234 |
| RegeneRx Biopharmaceuticals enrols first patients in ARISE-2 trial of RGN-259. |
|
|
Nov 11, 2016 |
230 |
| United States : Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX) in Combination with carfilzo0mib. |
|
|
Nov 11, 2016 |
626 |
| RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. |
|
|
Nov 10, 2016 |
303 |
| RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. |
|
|
Nov 10, 2016 |
299 |
| Janssen Announces Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate daratumumab (DARZALEX) in Combination with carfilzomib (KYPROLIS). |
|
|
Nov 10, 2016 |
2643 |
| United States : Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS in Frontline Mature T-cell Lymphoma. |
|
|
Nov 9, 2016 |
574 |
| Japan : Seattle Genetics and Takeda complete enrollment of phase 3 ECHELON-2 clinical trial evaluating ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell Lymphoma. |
|
|
Nov 9, 2016 |
578 |
| RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259. |
|
|
Nov 9, 2016 |
1435 |
| First data from dry-AMD trial to be presented in December. |
|
|
Nov 7, 2016 |
412 |
| Mereo BioPharma's acumapimod reports positive results for Phase one drug interaction study. |
|
Report |
Nov 7, 2016 |
117 |
| Mereo BioPharma's acumapimod reports positive results for Phase one drug interaction study. |
|
Report |
Nov 7, 2016 |
113 |
| Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder. |
|
|
Nov 1, 2016 |
1680 |
| First data from dry-AMD trial to be presented in December. |
|
|
Oct 31, 2016 |
412 |
| First data from Dry-AMD trial to be presented in December. |
|
|
Oct 31, 2016 |
412 |
| Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma. |
|
|
Oct 30, 2016 |
888 |
| Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma. |
|
|
Oct 30, 2016 |
851 |
| Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP). |
|
|
Oct 25, 2016 |
1841 |
| Array BioPharma And Pierre Fabre To Present Phase 3 COLUMBUS Trial At Society For Melanoma Research Annual Congress. |
|
|
Oct 25, 2016 |
1732 |
| United States : Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy (FTC/TAF)-Based Regimens from Truvada (FTC/TDF)-Based Regimens. |
|
|
Oct 25, 2016 |
310 |
| Theravance Biopharma's and Mylan's jointly developed revefenacin drug indicates benefits in phase three trials. |
|
|
Oct 24, 2016 |
208 |
| Theravance Biopharma's and Mylan's jointly developed revefenacin drug indicates benefits in phase three trials. |
|
|
Oct 24, 2016 |
204 |
| United States : Theravance biopharma and Mylan announce positive results from two pivotal phase 3 studies of revefenacin (td-4208) for the treatment of chronic obstructive pulmonary disease (copd). |
|
|
Oct 21, 2016 |
323 |
| United States : Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD). |
|
Financial report |
Oct 21, 2016 |
340 |
| Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). |
|
|
Oct 20, 2016 |
3057 |
| Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD). |
|
|
Oct 20, 2016 |
3105 |
| Sinovac Product Pipeline News. |
|
|
Oct 19, 2016 |
940 |
| First Ever Human Trial of a Live Attenuated Functioning Therapeutic Herpes Vaccine. |
|
|
Oct 17, 2016 |
915 |
| Theravance Biopharma doses first patient in Phase 1b clinical trial of TD-1473. |
|
|
Oct 6, 2016 |
228 |
| Theravance Biopharma doses first patient in Phase 1b clinical trial of TD-1473. |
|
|
Oct 6, 2016 |
224 |
| RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome. |
|
|
Sep 30, 2016 |
833 |
| DS Biopharma Will Today Present Data on a Phase IIa Study at the European Academy of Dermatology and Venereology (EADV) Congress. |
|
|
Sep 29, 2016 |
239 |
| Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint. |
|
|
Sep 26, 2016 |
2268 |
| Novavax fails to meet phase three trial objectives in RSV F-protein recombinant nanoparticle vaccine. |
|
|
Sep 19, 2016 |
247 |
| Novavax fails to meet phase three trial objectives in RSV F-protein recombinant nanoparticle vaccine. |
|
|
Sep 19, 2016 |
243 |
| Enteris BioPharma's "Feasibility to Licensing" Partner, Cara Therapeutics, Advances Peptelligence(TM)-Engineered CR845 into Phase 2b Clinical Trial in Chronic Pain. |
|
|
Sep 19, 2016 |
848 |
| LEUKOCARE Grants License to US Vaccine Company PaxVax. |
|
|
Sep 13, 2016 |
505 |
| LEUKOCARE Grants License to US Vaccine Company PaxVax. |
|
|
Sep 13, 2016 |
510 |
| Immunovaccine treats first recurrent ovarian cancer patient under Phase 1b clinical trial triple combination study. |
|
|
Sep 9, 2016 |
313 |
| Immunovaccine treats first recurrent ovarian cancer patient under Phase 1b clinical trial triple combination study. |
|
|
Sep 9, 2016 |
309 |
| Array BioPharma submits NDA for binimetinib with the US FDA for advanced NRAS-mutant melanoma. |
|
|
Sep 2, 2016 |
314 |
| Array BioPharma submits NDA for binimetinib with the US FDA for advanced NRAS-mutant melanoma. |
|
|
Sep 2, 2016 |
310 |
| Biogen and Ionis Pharmaceuticals Phase III trial evaluating nusinersen in infantile-onset (consistent with Type 1) spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis. |
|
|
Sep 1, 2016 |
155 |
| United States : CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis. |
|
|
Aug 30, 2016 |
168 |
| Palatin Technologies reports last HSDD patient visit under Phase 3 clinical trials of bremelanotide. |
|
|
Aug 5, 2016 |
232 |
| Palatin Technologies reports last HSDD patient visit under Phase 3 clinical trials of bremelanotide. |
|
|
Aug 5, 2016 |
228 |
| Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder. |
|
|
Aug 4, 2016 |
846 |
| VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease. |
|
|
Aug 2, 2016 |
1450 |
| Japan : Takeda and Seattle Genetics announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma. |
|
|
Aug 2, 2016 |
191 |
| Japan,United States : Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma. |
|
|
Aug 2, 2016 |
189 |
| LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA. |
|
|
Jul 26, 2016 |
548 |
| CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress. |
|
|
Jul 26, 2016 |
2087 |
| Japan,United States : Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood. |
|
|
Jul 19, 2016 |
439 |
| Japan : Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood. |
|
|
Jul 19, 2016 |
498 |
| Array BioPharma submits first NDA for binimetinib for treating melanoma. |
|
|
Jul 1, 2016 |
265 |
| Second patient cohort approved in clinical trial for dry AMD. |
|
|
Jun 20, 2016 |
342 |
| Theravance Biopharma's Phase 1 clinical trial of TD-1473 reveals positive results. |
|
|
Jun 13, 2016 |
200 |
| Theravance Biopharma's Phase 1 clinical trial of TD-1473 reveals positive results. |
|
|
Jun 13, 2016 |
196 |
| DSMB approves second patient cohort in clinical trial for dry AMD. |
|
|
Jun 13, 2016 |
343 |
| DSMB approves second patient cohort in clinical trial for dry AMD. |
|
|
Jun 13, 2016 |
344 |
| Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting. |
|
|
Jun 6, 2016 |
2208 |
| Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial. |
|
|
Jun 4, 2016 |
1699 |
| Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial. |
|
|
Jun 4, 2016 |
2181 |
| Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial. |
|
|
Jun 4, 2016 |
1695 |
| Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative Breast Cancer. |
|
|
Jun 2, 2016 |
2142 |
| Qiagen signs licensing and co-development agreement with Therawis Diagnostics. |
|
|
May 26, 2016 |
171 |
| Qiagen signs licensing and co-development agreement with Therawis Diagnostics. |
|
|
May 26, 2016 |
167 |
| One year Cohort I data from Phase 2 Pathway SCI study. |
|
Clinical report |
May 16, 2016 |
211 |
| One year Cohort I data from Phase 2 Pathway SCI Study. |
|
Clinical report |
May 16, 2016 |
211 |
| RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye. |
|
|
May 6, 2016 |
1824 |
| Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma. |
|
|
May 2, 2016 |
1211 |
| Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma. |
|
|
May 2, 2016 |
1206 |
| Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment. |
|
|
Apr 20, 2016 |
1417 |
| Positive interim results from Phase 2 study in spinal cord injury. |
|
|
Apr 18, 2016 |
437 |
| Positive interim results from phase 2 study in spinal cord injury. |
|
|
Apr 18, 2016 |
437 |
| BioInvent announces readiness to commence multiple myeloma Phase II study of antibody BI-505. |
|
Report |
Apr 18, 2016 |
314 |
| BioInvent announces readiness to commence multiple myeloma Phase II study of antibody BI-505. |
|
Report |
Apr 18, 2016 |
310 |
| Guardant Health Announces Collaboration With Principia Biopharma To Use Guardant360 for Monitoring Patient Response and Tumor Evolution in FGFR Inhibitor Trials. |
|
|
Mar 29, 2016 |
506 |
| Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer. |
|
|
Mar 24, 2016 |
1975 |
| Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy. |
|
|
Mar 23, 2016 |
653 |
| Biocept to Collaborate on Biopharma Company Clinical Trial by Identifying Biomarkers Found in Cerebral Spinal Fluid for Patients with Lung Cancer that has Spread to the Brain. |
|
|
Mar 21, 2016 |
1077 |
| Global Cancer Vaccines Clinical Pipeline 2015 by Phase, Indication, Company & Country. |
|
|
Mar 1, 2016 |
1631 |
| Global Cancer Vaccines Clinical Pipeline 2015 by Phase, Indication, Company & Country. |
|
|
Mar 1, 2016 |
1671 |
| Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. |
|
|
Feb 29, 2016 |
156 |
| Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. |
|
|
Feb 29, 2016 |
152 |
| Seattle Genetics commences vadastuximab talirine clinical trials. |
|
|
Feb 24, 2016 |
204 |
| Seattle Genetics commences vadastuximab talirine clinical trials. |
|
|
Feb 24, 2016 |
200 |
| CTI BioPharma Provides Update On Investigational Agent Pacritinib. |
|
Clinical report |
Feb 8, 2016 |
1046 |
| RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial. |
|
|
Jan 29, 2016 |
1089 |
| Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer. |
|
|
Jan 26, 2016 |
1780 |
| AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer. |
|
Financial report |
Jan 26, 2016 |
1127 |
| Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial. |
|
|
Jan 19, 2016 |
1306 |
| Gilead Sciences submits NDA for tenofovir alafenamide to US FDA for treating chronic hepatitis B virus. |
|
|
Jan 13, 2016 |
268 |
| Gilead Sciences submits NDA for tenofovir alafenamide to US FDA for treating chronic hepatitis B virus. |
|
|
Jan 13, 2016 |
264 |
| Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer. |
|
|
Jan 13, 2016 |
1751 |
| Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy. |
|
|
Jan 12, 2016 |
2014 |
| Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction. |
|
|
Jan 12, 2016 |
1636 |
| DS Biopharma Announces Positive Top-line Phase IIa Trial Results for DS107 as an Oral Treatment for Moderate to Severe Atopic Dermatitis. |
|
Clinical report |
Jan 7, 2016 |
585 |
| Yisheng Biopharma announces results from Phase I clinical trial of PIKA rabies vaccine. |
|
|
Jan 5, 2016 |
171 |
| Yisheng Biopharma announces results from Phase I clinical trial of PIKA rabies vaccine. |
|
|
Jan 5, 2016 |
167 |
| Seattle Genetics and Bristol-Myers Squibb assess Adcetris in combination with Opdivo with commencement of new trial. |
|
|
Dec 24, 2015 |
201 |
| Seattle Genetics and Bristol-Myers Squibb assess Adcetris in combination with Opdivo with commencement of new trial. |
|
|
Dec 24, 2015 |
197 |
| DS Biopharma Announces Successful Completion of a Phase I Safety Study With Bioactive Lipid DS102 Which is Targeting NASH and IPF. |
|
|
Dec 18, 2015 |
376 |
| Novavax commences clinical trial of RSV F Vaccine. |
|
|
Dec 16, 2015 |
247 |
| Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia. |
|
|
Dec 16, 2015 |
227 |
| Novavax commences clinical trial of RSV F Vaccine. |
|
|
Dec 16, 2015 |
243 |
| Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia. |
|
|
Dec 16, 2015 |
223 |
| Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma. |
|
|
Dec 16, 2015 |
1267 |
| Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. |
|
|
Dec 15, 2015 |
770 |
| Theravance Biopharma doses first patient in Phase 1 clinical trial of TD-1473. |
|
|
Dec 14, 2015 |
142 |
| Theravance Biopharma doses first patient in Phase 1 clinical trial of TD-1473. |
|
|
Dec 14, 2015 |
138 |
| Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction. |
|
|
Dec 10, 2015 |
961 |
| CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition. |
|
|
Dec 7, 2015 |
1236 |
| CEL-SCI admits 27 patients in November under ongoing Phase 3 trial of investigational immunotherapy Multikine for advanced primary squamous cell carcinoma of primary head and neck cancer. |
|
|
Dec 2, 2015 |
261 |
| CEL-SCI admits 27 patients in November under ongoing Phase 3 trial of investigational immunotherapy Multikine for advanced primary squamous cell carcinoma of primary head and neck cancer. |
|
|
Dec 2, 2015 |
257 |
| Canada : With PhIII trial coming up, Infinity strikes risk-based monitoring deal with Medidata. |
|
|
Dec 1, 2015 |
323 |
| CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS. |
|
Clinical report |
Nov 24, 2015 |
1464 |
| CTI BioPharma Announces Presentation of Preclinical Data Demonstrating Potential Synergistic Combination of Pacritinib and an EGFR Inhibitor in Targeting Brain Tumor Initiating Cells. |
|
|
Nov 23, 2015 |
1295 |
| Array BioPharma signs cancer drug development agreement with Pierre Fabre. |
|
|
Nov 18, 2015 |
176 |
| Array BioPharma signs cancer drug development agreement with Pierre Fabre. |
|
|
Nov 18, 2015 |
172 |
| Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus. |
|
|
Nov 17, 2015 |
1006 |
| US FDA grants approval for Genentech's melanoma drug. |
|
|
Nov 12, 2015 |
190 |
| US FDA grants approval for Genentech's melanoma drug. |
|
|
Nov 12, 2015 |
186 |
| Heraeus Medical and OrthoCyte partner to create bone-grafting therapies. |
|
|
Nov 1, 2015 |
545 |
| Dr. Robert Pyke from S1 Biopharma to Present at ExL Pharma CNS Clinical Trial Forum. |
|
|
Oct 31, 2015 |
419 |
| Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C. |
|
|
Oct 29, 2015 |
260 |
| Gilead submits NDA to US FDA for once daily fixed-dose combination of sofosbuvir/velpatasvir for treating six genotypes of hepatitis C. |
|
|
Oct 29, 2015 |
256 |
| Japan : Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Previously Untreated Advanced Hodgkin Lymphoma (HL). |
|
|
Oct 29, 2015 |
475 |
| Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate. |
|
|
Oct 26, 2015 |
1082 |
| RegeneRx Updates on Asian Ophthalmic Clinical Trials. |
|
|
Oct 23, 2015 |
1208 |
| RegeneRx Updates on U.S. Ophthalmic Clinical Trials. |
|
|
Oct 21, 2015 |
1103 |
| Theravance Biopharma submits IND application to the US FDA to conduct first-in-human study of TD-0714 in cardiovascular and renal diseases. |
|
|
Oct 14, 2015 |
278 |
| Theravance Biopharma submits IND application to the US FDA to conduct first-in-human study of TD-0714 in cardiovascular and renal diseases. |
|
|
Oct 14, 2015 |
274 |
| RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial. |
|
|
Sep 30, 2015 |
949 |
| Novavax Announces Positive Top-Line Data from Phase 2 Clinical Trial of RSV F Vaccine to Protect Infants via Maternal Immunization. |
|
|
Sep 29, 2015 |
1542 |
| Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting. |
|
|
Sep 28, 2015 |
794 |
| CTI BioPharma to submit NDA to the US FDA for pacritinib for treating patients with myelofibrosis and low platelet counts. |
|
|
Sep 24, 2015 |
348 |
| CTI BioPharma to submit NDA to the US FDA for pacritinib for treating patients with myelofibrosis and low platelet counts. |
|
|
Sep 24, 2015 |
352 |
| CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial. |
|
|
Sep 23, 2015 |
1617 |
| RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259. |
|
|
Sep 21, 2015 |
1402 |
| RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259. |
|
|
Sep 16, 2015 |
1306 |
| Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD). |
|
|
Sep 14, 2015 |
2255 |
| Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide in Phase 2 Trial in Osteoarthritis. |
|
|
Aug 20, 2015 |
540 |
| Regen BioPharma Inc. Progresses in FDA Responses to dCellVax Clinical Trial Questions. |
|
|
Aug 10, 2015 |
689 |
| Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults. |
|
Clinical report |
Aug 10, 2015 |
1832 |
| RegeneRx Provides Update on Clinical Trials in U.S., Korea and China. |
|
|
Aug 6, 2015 |
981 |
| CEL-SCI announces record July patient enrollment under its Phase 3 head and neck cancer trial. |
|
|
Aug 4, 2015 |
321 |
| CEL-SCI announces record July patient enrollment under its Phase 3 head and neck cancer trial. |
|
|
Aug 4, 2015 |
317 |
| Korea approves phase 2b/3 clinical trial in patients with Dry Eye syndrome. |
|
|
Aug 3, 2015 |
286 |
| Korea approves phase 2b/3 clinical trial in patients with dry eye syndrome. |
|
|
Jul 27, 2015 |
287 |
| Korea approves phase 2b/3 trial in patients with dry eye syndrome. |
|
|
Jul 27, 2015 |
287 |
| Novavax reveals favorable top-line data from Phase I clinical trial of Ebola virus glycoprotein recombinant nanoparticle vaccine candidate. |
|
|
Jul 24, 2015 |
177 |
| Novavax reveals favorable top-line data from Phase I clinical trial of Ebola virus glycoprotein recombinant nanoparticle vaccine candidate. |
|
|
Jul 24, 2015 |
173 |
| MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections. |
|
|
Jul 21, 2015 |
766 |
| MGB Biopharma Commences Phase I Clinical Trial With Oral Formulation of MGB-BP-3 for the Treatment of Multi-Resistant Clostridium Difficile Infections. |
|
|
Jul 21, 2015 |
771 |
| RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome. |
|
|
Jul 17, 2015 |
1129 |
| Seattle Genetics starts a Phase II clinical trial of Adcetris. |
|
|
Jul 14, 2015 |
163 |
| Seattle Genetics starts a Phase II clinical trial of Adcetris. |
|
|
Jul 14, 2015 |
159 |
| Health Canada okays Phase 2 cervical spinal cord injury study. |
|
|
Jul 6, 2015 |
222 |
| Semi-Permeable Films Pipeline Review 2015 Market Research Report. |
|
|
Jul 3, 2015 |
1224 |
| Gilead Sciences submits NDA to the US FDA for once-daily single tablet regimen of emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) for HIV-1 infection. |
|
|
Jul 2, 2015 |
353 |
| Gilead Sciences submits NDA to the US FDA for once-daily single tablet regimen of emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) for HIV-1 infection. |
|
|
Jul 2, 2015 |
349 |
| Positive results from phase 1/2 dry AMD study. |
|
|
Jun 29, 2015 |
432 |
| Health Canada okays Phase 2 cervical spinal cord injury study. |
|
|
Jun 29, 2015 |
221 |
| Positive results from phase 1/2 dry AMD study. |
|
|
Jun 29, 2015 |
431 |
| Health Canada okays Phase 2 cervical spinal cord injury study. |
|
|
Jun 29, 2015 |
221 |
| Helix BioPharma starts patient enrolment for thirteenth dose level group in Polish Phase I/II trial of L-DOS47. |
|
|
Jun 24, 2015 |
223 |
| Helix BioPharma starts patient enrolment for thirteenth dose level group in Polish Phase I/II trial of L-DOS47. |
|
|
Jun 24, 2015 |
219 |
| Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer. |
|
|
Jun 10, 2015 |
601 |
| Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study Of Probuphine For Opioid Addiction. |
|
Clinical report |
Jun 8, 2015 |
1910 |
| Pharming Announces Interim Results From the Ongoing Phase II Pediatric Clinical Trial of RUCONEST. |
|
|
Jun 1, 2015 |
1430 |
| Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology. |
|
Clinical report |
May 22, 2015 |
1159 |
| Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial. |
|
|
Apr 29, 2015 |
835 |
| CryoLife Announces Enrollment of First Patient in PerClot IDE Clinical Trial. |
|
|
Apr 28, 2015 |
1144 |
| CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO. |
|
|
Apr 22, 2015 |
1742 |
| RegeneRx Biopharmaceuticals' US JV retains Ora to conduct Phase III trial of RGN-259/GBT201. |
|
|
Apr 21, 2015 |
173 |
| RegeneRx Biopharmaceuticals' US JV retains Ora to conduct Phase III trial of RGN-259/GBT201. |
|
|
Apr 21, 2015 |
169 |
| RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. |
|
|
Apr 16, 2015 |
1446 |
| RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea. |
|
|
Apr 1, 2015 |
768 |
| Biogen Idec reports positive interim results from Phase Ib PRIME trial of aducanumab. |
|
|
Mar 24, 2015 |
175 |
| Biogen Idec reports positive interim results from Phase Ib PRIME trial of aducanumab. |
|
|
Mar 24, 2015 |
171 |
| CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis. |
|
Clinical report |
Mar 16, 2015 |
1937 |
| Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial. |
|
|
Mar 11, 2015 |
689 |
| CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis. |
|
Financial report |
Mar 9, 2015 |
2745 |
| First Patient Treated In Trial Of Matrix For Lipoatrophy. |
|
|
Mar 9, 2015 |
177 |
| Theravance Biopharma collaborates with Mylan to develop and commercialise TD-4208. |
|
|
Feb 4, 2015 |
154 |
| Theravance Biopharma collaborates with Mylan to develop and commercialise TD-4208. |
|
|
Feb 4, 2015 |
150 |
| RegeneRx Biopharmaceuticals signs contracts with G-treeBNT. |
|
|
Jan 30, 2015 |
169 |
| RegeneRx Biopharmaceuticals signs contracts with G-treeBNT. |
|
|
Jan 30, 2015 |
165 |
| Steatohepatitis Therapeutics Clinical Trials Market H1 2015 Review Report at RnRMarketResearch.com. |
|
|
Jan 30, 2015 |
1022 |
| Synageva BioPharma starts dosing in Phase I/II trial with SBC-103. |
|
|
Jan 28, 2015 |
206 |
| Synageva BioPharma starts dosing in Phase I/II trial with SBC-103. |
|
|
Jan 28, 2015 |
202 |
| RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S. |
|
|
Jan 28, 2015 |
1031 |
| WCCT Global signs clinical trial partnership with Dynport Vaccine. |
|
|
Jan 26, 2015 |
118 |
| WCCT Global signs clinical trial partnership with Dynport Vaccine. |
|
|
Jan 26, 2015 |
114 |
| Canada : Health Canada Clears Immunovaccine to Conduct Phase I Clinical Trial of Respiratory Syncytial Virus (RSV) Vaccine. |
|
|
Jan 22, 2015 |
440 |
| BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. |
|
|
Jan 20, 2015 |
437 |
| BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. |
|
|
Jan 20, 2015 |
433 |
| G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. |
|
|
Dec 30, 2014 |
195 |
| G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. |
|
|
Dec 30, 2014 |
191 |
| Palatin Announces Start of Bremelanotide Phase 3 Program For Female Sexual Dysfunction. |
|
|
Dec 29, 2014 |
1237 |
| RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome. |
|
|
Dec 29, 2014 |
1037 |
| Cerus' Intercept Meets Endpoint in Phase 2 Clinical Trial. |
|
|
Dec 22, 2014 |
297 |
| Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis (Carfilzomib) In Patients With Relapsed Multiple Myeloma. |
|
Clinical report |
Dec 6, 2014 |
3715 |
| MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting. |
|
|
Dec 6, 2014 |
1534 |
| Galena Biopharma completes patient enrollment in GALE-401 Phase II clinical trial. |
|
|
Nov 20, 2014 |
121 |
| Galena Biopharma completes patient enrollment in GALE-401 Phase II clinical trial. |
|
|
Nov 20, 2014 |
117 |
| MorphoSys receives fast track designation for MOR208 from US Food and Drug Administration. |
|
|
Nov 11, 2014 |
187 |
| Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting. |
|
|
Nov 10, 2014 |
2331 |
| Clinical trials of 2 Ebola vaccines starts,results will be available in December. |
|
|
Oct 25, 2014 |
691 |
| Vaxart to commence human clinical trials of Ebola tablet vaccine in early 2105. |
|
|
Oct 23, 2014 |
302 |
| Vaxart to commence human clinical trials of Ebola tablet vaccine in early 2105. |
|
|
Oct 23, 2014 |
298 |
| Sutro Biopharma, Celgene join forces to discover, develop antibodies, ADCs. |
|
|
Oct 23, 2014 |
364 |
| RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy. |
|
|
Oct 20, 2014 |
1363 |
| CIRM grant will fund phase l/2a clinical trial stem cell SCI treatment. |
|
|
Oct 20, 2014 |
353 |
| CIRM grant will fund phase 1/2a clinical trial of stem cell so treatment. |
|
|
Oct 20, 2014 |
353 |
| MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma. |
|
|
Sep 25, 2014 |
991 |
| Inovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science. |
|
|
Sep 24, 2014 |
1272 |
| Sutro Biopharma, Merck KGaA to jointly develop antibody drug conjugates. |
|
|
Sep 17, 2014 |
258 |
| Asterias Biotherapeutics begins next phase of cervical SCI trial. |
|
|
Sep 1, 2014 |
439 |
| Traumatic Spinal Cord Injury Global Clinical Trials Review, H2, 2014. |
|
|
Aug 25, 2014 |
1735 |
| Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck. |
|
|
Aug 20, 2014 |
1662 |
| United States : Amgen Announces Top-line Results from Phase 3 FOCUS Trail of KYPROLIS in Patients with Relapsed and Advanced Refractory Multiple Myeloma. |
|
Financial report |
Aug 14, 2014 |
241 |
| Amgen Announces Top-Line Results From Phase 3 Focus Trial Of Kyprolis In Patients With Relapsed And Advanced Refractory Multiple Myeloma. |
|
|
Aug 13, 2014 |
2559 |
| Spinal Cord Injury Global Clinical Trials Review, H2, 2014. |
|
|
Aug 11, 2014 |
2032 |
| Multiple Sclerosis Global Clinical Trials Review, H2, 2014. |
|
|
Aug 5, 2014 |
1966 |
| Muscle Spasticity Global Clinical Trials Review, H2, 2014. |
|
|
Aug 5, 2014 |
1914 |
| United Kingdom : Amgen Announces Phase 3 ASPIRE Trial of Kyprolis in Patients with Relapsed Multiple Myeloma Met Primary Endpoint. |
|
|
Aug 5, 2014 |
111 |
| Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis In Patients With Relapsed Multiple Myeloma Met Primary Endpoint. |
|
|
Aug 4, 2014 |
2864 |
| Incyte signs clinical trial agreement with Genentech. |
|
|
Aug 1, 2014 |
149 |
| Incyte signs clinical trial agreement with Genentech. |
|
|
Aug 1, 2014 |
145 |
